- Home
- MATV vs FULC Comparison
MATV vs FULC Comparison
Compare MATV & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MATV | FULC |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.0M | 718.4M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MATV | FULC |
|---|---|---|
| Price | $9.18 | $7.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $16.38 |
| AVG Volume (30 Days) | 327.3K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.97 | N/A |
| Revenue Next Year | $4.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.34 | $2.32 |
| 52 Week High | $15.48 | $15.74 |
Technical Indicators
Market Signals| Indicator | MATV | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 23.78 | 35.59 |
| Support Level | $5.91 | $6.33 |
| Resistance Level | $13.20 | $8.50 |
| Average True Range (ATR) | 0.62 | 0.75 |
| MACD | -0.29 | -0.14 |
| Stochastic Oscillator | 4.71 | 10.64 |
Price Performance
Historical ComparisonAbout MATV Mativ Holdings Inc.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.